Psychedelics are psychoactive substances that can alter perception, emotions, thinking, and the experience of consciousness. They have long been used in various cultural and ritual contexts, and in recent years, their potential therapeutic effects have attracted increasing scientific interest.
Psilocybin, LSD, and other classic psychedelics have received particular attention. MDMA has also been studied as an aid to psychotherapy, especially in the treatment of post-traumatic stress disorder (PTSD). However, MDMA works differently from classic psychedelics, so these substances should not be treated as a single, uniform group.
Clinical studies have produced promising results, particularly in the treatment of depression and PTSD. However, the evidence remains partly uncertain, and the benefits observed in research cannot be generalized to everyone or to unsupervised use.
Psychedelics and Mental Health
Psilocybin and the Treatment of Depression
Psilocybin is one of the most extensively studied psychedelic compounds in mental health research. Clinical studies have observed reductions in depressive symptoms among participants receiving psilocybin-assisted treatment, including in some cases of treatment-resistant depression.
Some studies have found effects soon after treatment. For certain participants, the benefits have persisted for weeks or months. However, results vary between studies, and more research is needed to establish the long-term effects and determine the most effective treatment protocols.
In clinical research, psilocybin-assisted therapy generally involves preparation, a supervised treatment session, and subsequent integration sessions. The findings therefore should not be interpreted as evidence that psilocybin on its own is an established or universally accepted treatment for depression.
A research review published in 2025 found that psilocybin reduced depressive symptoms compared with control treatments. However, methodological limitations and potential sources of bias affected the certainty of the findings.
MDMA and Post-Traumatic Stress Disorder
MDMA has been studied particularly in the treatment of post-traumatic stress disorder, or PTSD. Research has found reductions in PTSD symptoms among participants receiving MDMA-assisted therapy.
MDMA affects the serotonin system, among other processes, and can alter emotional processing and experiences of social interaction. Researchers are investigating how these effects might support psychotherapeutic work.
However, the findings must be interpreted cautiously. Study sizes, participant selection, expectancy effects, and treatment methods limit the conclusions that can be drawn. The psychological and physiological risks associated with the substance also require careful assessment.
MDMA-assisted therapy should not be equated with conventional psychotherapy or automatically regarded as an approved treatment. Its legal status and availability depend on the country and the applicable regulations.
Creativity, Openness, and Cognitive Flexibility
Psychedelics and Creativity
Psychedelic experiences are often associated with heightened imagination, the perception of new connections, and the questioning of habitual thought patterns. Some people report gaining new perspectives on art, music, or personal problems.
However, a subjective feeling of increased creativity is not the same as a demonstrated improvement in creative performance. Scientific evidence regarding psychedelics and creativity remains limited, and findings depend on factors such as study design and assessment methods.
At present, there is insufficient evidence to conclude that psychedelics reliably or consistently improve creativity over the long term in all individuals.
Emotional Openness and Empathy
Some people who describe their psychedelic experiences report increased emotional openness, a stronger sense of connection, and an ability to view things from new perspectives.
Researchers are investigating whether these experiences may be associated with psychological flexibility, emotional processing, and social well-being. However, effects differ between individuals, and a single experience does not automatically improve empathy or relationships.
The meaning of these experiences can be influenced by personal expectations, life circumstances, the surrounding environment, and subsequent reflection.
Consciousness and Personal Insights
Personal Growth and the Meaning of Experiences
Psychedelic experiences can involve intense emotions, unusual perceptions, and insights that feel deeply meaningful. Some people describe these experiences as changing their attitudes toward themselves, their relationships, or fundamental questions about life.
An experience may be personally significant, but its intensity alone does not establish that every interpretation formed during it is objectively accurate or that the experience will lead to lasting well-being.
In a therapeutic setting, integration can help people examine the meaning of their experiences and connect potential insights with everyday life. It can also provide an opportunity to address conflicting emotions and difficult experiences.
Long-Term Effects on Well-Being
Some clinical studies have found improvements in mood and anxiety symptoms that persisted for weeks or months after treatment. However, more research is needed to establish the long-term effects.
Researchers need to determine how long potential benefits last, which individuals are most likely to benefit, and what additional support may be needed to maintain improvements. Potential adverse effects must also be monitored, including prolonged anxiety, sleep disturbances, and rare but serious psychological reactions.
Psychedelics are not risk-free. They can cause intense fear, panic, or confusion. In some individuals, they may worsen existing psychological symptoms. Particular caution is necessary for people with a predisposition to psychosis or mania.
Set and Setting: Mindset and Environment
Psychedelic research frequently uses the term set and setting. It refers to a person’s mindset and expectations, as well as the environment in which an experience takes place.
Set refers to factors such as a person’s mood, expectations, life circumstances, and psychological preparation.
Setting refers to the environment in which the experience takes place, including safety, the people present, and the support available.
These factors may influence how an experience unfolds and how it is perceived. However, they cannot guarantee a positive outcome or eliminate the risks associated with these substances.
Clinical studies aim to improve safety through participant screening, trained personnel, supervised conditions, and follow-up care. These conditions differ substantially from unsupervised use.
Challenges in Psychedelic Research
Although some findings are promising, significant challenges remain in this field.
- Research quality: Many studies are small, and participants’ expectations can influence the results.
- Individual differences: The same substance can produce very different experiences and effects in different people.
- Long-term follow-up: More evidence is needed about the durability of benefits and the possibility of delayed adverse effects.
- Safety: Psychological reactions, interactions with other substances, and physiological risks require careful assessment.
- Treatment accessibility: Psychedelic-assisted therapy may require substantial professional time, specialized training, and resources.
- Regulation: The legal status of these substances, research permissions, and medical use vary between countries.
Treatment protocols used in clinical trials should not be equated with unsupervised use. Research findings also do not mean that a substance is legal or medically approved in any particular country.
The Future of Psychedelics in Medicine
Toward More Reliable Scientific Evidence
Psychedelic research has expanded, and researchers are working to determine the circumstances in which potential benefits are greatest and risks are acceptable.
Further studies aim to establish how these treatments compare with existing options, how long their effects last, and which patients might be suitable candidates.
Researchers are also investigating which components of treatment are essential: the substance itself, psychotherapeutic support, preparation, or the integration of the experience afterward.
More Personalized Treatment
An important research goal is to identify factors that predict treatment response and the risk of adverse effects. Biological differences, previous health conditions, psychological factors, and other medications may all influence whether a treatment is suitable.
A better understanding of individual differences could help researchers target treatments more effectively and identify situations in which potential risks outweigh the expected benefits.
Interdisciplinary Collaboration
Understanding psychedelics requires collaboration across neuroscience, psychology, psychiatry, pharmacology, and the social sciences.
Research may help clarify how these substances affect brain function, emotional processing, and the experience of consciousness. At the same time, researchers need to consider cultural meanings, ethical questions, and the practical implementation of treatments.
Conclusion: A Promising Field of Research, Not a Finished Solution
Psychedelics are an important area of scientific investigation. Research into psilocybin for depression and MDMA-assisted therapy for PTSD has produced promising results. However, uncertainties remain, and current evidence does not support every claim made about the potential benefits of psychedelics.
There are interesting personal accounts of effects involving creativity, empathy, and personal growth, but these areas require stronger scientific evidence.
The future of psychedelic research depends on establishing their benefits, limitations, and risks with sufficient reliability. The goal is not to treat psychedelics as a universal solution, but to determine where they might offer a safe and useful addition to mental health care.
References and Further Reading
- European Union Drugs Agency (EUDA): Therapeutic use of psychedelic substances — frequently asked questions
- Living systematic review (2025): Efficacy and acceptability of serotonergic psychedelics and MDMA to treat mental disorders
- Systematic review (2025): Incremental efficacy of psilocybin for depression
- European Union legislation: Directive 2001/83/EC on medicinal products for human use
Disclaimer: This article is intended to provide general, research-based information. It does not constitute medical advice or encourage the use of controlled substances. The legal status of these substances and their potential medical use depend on the applicable legislation.
